<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="" xml:lang="">
<head>
  <meta charset="utf-8" />
  <meta name="generator" content="pandoc" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=yes" />
  <meta name="author" content="Akshay Gulabrao" />
  <title>ABVX</title>
  <style>
    code{white-space: pre-wrap;}
    span.smallcaps{font-variant: small-caps;}
    div.columns{display: flex; gap: min(4vw, 1.5em);}
    div.column{flex: auto; overflow-x: auto;}
    div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
    /* The extra [class] is a hack that increases specificity enough to
       override a similar rule in reveal.js */
    ul.task-list[class]{list-style: none;}
    ul.task-list li input[type="checkbox"] {
      font-size: inherit;
      width: 0.8em;
      margin: 0 0.8em 0.2em -1.6em;
      vertical-align: middle;
    }
    /* CSS for citations */
    div.csl-bib-body { }
    div.csl-entry {
      clear: both;
      margin-bottom: 0em;
    }
    .hanging-indent div.csl-entry {
      margin-left:2em;
      text-indent:-2em;
    }
    div.csl-left-margin {
      min-width:2em;
      float:left;
    }
    div.csl-right-inline {
      margin-left:2em;
      padding-left:1em;
    }
    div.csl-indent {
      margin-left: 2em;
    }  </style>
  <link rel="stylesheet" href="style.css" />
</head>
<body>
<header id="title-block-header">
<h1 class="title">ABVX</h1>
<p class="author">Akshay Gulabrao</p>
<p class="date">2025 September 16</p>
</header>
<p><a href="./index.html">Home</a></p>
<h2 id="ulcerative-colitis">Ulcerative Colitis</h2>
<p>The primary endpoint for ulcerative colitis is measured by
qualitative symptoms of stool frequency, rectal bleeding, mucosal
appearance, and a physician’s rating. <span class="citation"
data-cites="UlcerativeColitisClinical2016">(<a
href="#ref-UlcerativeColitisClinical2016"
role="doc-biblioref"><span>“Ulcerative <span>Colitis</span>:
<span>Clinical Trial Endpoints Guidance</span> for
<span>Industry</span>”</span> 2016</a>)</span>.</p>
<h2 id="obefazimod">Obefazimod</h2>
<p>Obefazimod started off as an HIV drug and now is an Ulcerative
Colitis (UC) drug <span class="citation"
data-cites="camposLongLastingControl2015">(<a
href="#ref-camposLongLastingControl2015" role="doc-biblioref">Campos et
al. 2015</a>)</span> <span class="citation" data-cites="tazi2010">(<a
href="#ref-tazi2010" role="doc-biblioref">Tazi et al. 2010</a>)</span>.
Then in 2017, it was discovered to have anti-inflammatory properties.
<span class="citation" data-cites="Chebli2017">(<a
href="#ref-Chebli2017" role="doc-biblioref">Chebli et al.
2017</a>)</span> They used dextran sulfate sodium to cause colitis in
mice, and then administered their drug ABX464. They measured efficicacy
by tracking IL-6, TNFα and MCP-1.</p>
<p><img src="./media/campos_fig1.png" /> The paper starts by measuring
the effectiveness of ABX464 for treating DSS-induced colitis. There 2
variables that they must manage, the ABX464 efficacy, and the efficacy
of the DSS. As a result they have 4 total groups consisting of: {(no
disease, no drug), (no diesease, drug), (disease, no drug),
(disease,drug)}. Figure A describes the administration protocol. They
give the drug for 8 days and then wait 3 days before analyzing the
results. Figure B measures the relative weight of the mice. We can
observe that when DSS is given, the weight begins to decline for the
both the metylcellulose control and the ABX464.</p>
<p><img src="./media/campos_fig2.png" /> Then in another study, they
administered the DSS for a total of 60 days. and ran 3 groups: ABX64,
ABX64 then control, and just control. Figure 2b shows that mice with
only MC quickly declined in health.</p>
<p><img src="./media/campos_fig3.png" /> Figure 3b shows a control image
of the colon and the difference of ABX464 vs the DSS + MC. We see less
lesions in 3b. 3cdef shows inflammatory markers for both the MC control
and the ABX464 drug.</p>
<p><img src="./media/campos_fig4.png" /> 4a shows that ABVX works
completely identical to control when no DSS is shown. 4b shows the gene
expression patterns when DSS is present with the control treatement,
showing a wide varianc in the difference of expression during. 4c shows
some reversion back to 4a, which is the gene expression when treated
with ABVX. The arrow indicates the expression of IL-22, which seems to
dampen the intestinal inflammation when it’s expressed.</p>
<p><img src="./media/campos_fig5.png" /> There are two distinct
variables in this experimental run: the LPS and the drug. So there are 4
groups, (LPS, control) x (ABX464, DMSO (control)).This measures the
transcription levels of four inflammation markers: (1) MCP-1, (2) IL-6,
(3) TNF-α, (4) IL-10. For MCP-1, we see that the LPS + DMSO steadily
rise for both, with the ABX464 lower after 48 hours. For IL-6, We see
Similar levels for both. For TNF alpha, we see high levels after 6 hours
for both, and negligible for the rest. For IL-10, we see LPS ABX 464
declining after 12 hours.</p>
<p><img src="./media/campos_fig6.png" /></p>
<h2 class="unnumbered" id="references">References</h2>
<div id="refs" class="references csl-bib-body hanging-indent"
data-entry-spacing="0" role="list">
<div id="ref-camposLongLastingControl2015" class="csl-entry"
role="listitem">
Campos, Noëlie, Renier Myburgh, Aude Garcel, Audrey Vautrin, Laure
Lapasset, Erika Schläpfer Nadal, Florence Mahuteau-Betzer, et al. 2015.
<span>“Long Lasting Control of Viral Rebound with a New Drug
<span>ABX464</span> Targeting <span>Rev</span> – Mediated Viral
<span>RNA</span> Biogenesis.”</span> <em>Retrovirology</em> 12 (1): 30.
<a
href="https://github.com/akshaygulabrao/ABVX/blob/main/abx464_mediated_viral_RNA_biogenesis.pdf">https://github.com/akshaygulabrao/ABVX/blob/main/abx464_mediated_viral_RNA_biogenesis.pdf</a>.
</div>
<div id="ref-Chebli2017" class="csl-entry" role="listitem">
Chebli, Karim, Laura Papon, Conception Paul, Aude Garcel, Noëlie Campos,
Didier Scherrer, Hartmut J. Ehrlich, Michael Hahne, and Jamal Tazi.
2017. <span>“The Anti-HIV Candidate Abx464 Dampens Intestinal
Inflammation by Triggering Il-22 Production in Activated
Macrophages.”</span> <em>Scientific Reports</em> 7: 4860. <a
href="https://github.com/akshaygulabrao/ABVX/blob/main/abx464_dampens_intestinal_inflammation.pdf">https://github.com/akshaygulabrao/ABVX/blob/main/abx464_dampens_intestinal_inflammation.pdf</a>.
</div>
<div id="ref-tazi2010" class="csl-entry" role="listitem">
Tazi, Jamal, Nadia Bakkour, Virginie Marchand, Lilia Ayadi, Amina
Aboufirassi, and Christiane Branlant. 2010. <span>“Alternative Splicing:
Regulation of HIV-1 Multiplication as a Target for Therapeutic
Action.”</span> <a
href="https://github.com/akshaygulabrao/ABVX/blob/main/target_HIV1_replication.pdf">https://github.com/akshaygulabrao/ABVX/blob/main/target_HIV1_replication.pdf</a>.
</div>
<div id="ref-UlcerativeColitisClinical2016" class="csl-entry"
role="listitem">
<span>“Ulcerative <span>Colitis</span>: <span>Clinical Trial Endpoints
Guidance</span> for <span>Industry</span>.”</span> 2016. <a
href="https://www.fda.gov/files/drugs/published/Ulcerative-Colitis--Clinical-Trial-Endpoints-Guidance-for-Industry.pdf">https://www.fda.gov/files/drugs/published/Ulcerative-Colitis--Clinical-Trial-Endpoints-Guidance-for-Industry.pdf</a>.
</div>
</div>
</body>
</html>
